Albenatide vs HDG1901
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
Albenatide
Developed by ConjuChem and partners
NCT07058545 · Phase 3 · completed
The study randomized 474 participants to CJC-1134-PC or placebo and blinded participants, care providers, investigators, and outcome assessors. Its primary endpoint was change in HbA1c at Week 25, a surrogate measure, and the registry does not report whether the comparison was favorable or statistically significant.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
No aligned efficacy figure on record for this race.
HDG1901
Developed by Hangzhou Zhongmei Huadong Pharmaceutical
NCT06739044 · Phase 3 · completed
This randomized, open-label Phase 3 trial compared HDG1901, a semaglutide biosimilar, with Ozempic in 490 adults with type 2 diabetes on metformin. The primary endpoint was the change in HbA1c at week 32, tested for equivalence with a margin of 0.4%. HbA1c fell by 2.047% with HDG1901 and 2.008% with Ozempic, a difference of -0.038% (95% CI -0.189 to 0.112). The whole confidence interval was inside the margin, so the trial showed equivalence. The figures come from the published ADA 2025 conference abstract.
Reported efficacy
Change in HbA1c from baseline (Week 32): HbA1c change from baseline to week 32 (equivalence, margin ±0.4%): HDG1901 -2.047% vs Ozempic -2.008%; treatment difference -0.038% (95% CI -0.189 to 0.112), within the margin, met. (met)
Result source: NCT06739044
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Albenatide | HDG1901 |
|---|---|---|
| HbA1c, change | -0.8% vs -0.5%−0.4 vs placeboNCT006387161 other result
| -2.0% vs -2.0%avs reference OzempicNCT06739044 |
| Body weight, change (kg) | -2.0 vs -1.6−0.4 vs placeboNCT006387161 other result
| —Not posted · NCT06739044 |
| HbA1c below 7% | —Not posted · NCT07058545 | —Not posted · NCT06739044 |
| Fasting plasma glucose, change | -0.8 vs -0.6−0.2 vs placeboNCT006387161 other result
| —Not posted · NCT06739044 |
| 3-point MACE (% with event) | —Not posted · NCT07058545 | —Not posted · NCT06739044 |
HbA1c, change
- Albenatide
- -0.8% vs -0.5%−0.4 vs placeboNCT00638716
1 other result
- -1.3% vs -0.3% NCT00674466
- HDG1901
- -2.0% vs -2.0%avs reference OzempicNCT06739044
Body weight, change (kg)
- Albenatide
- -2.0 vs -1.6−0.4 vs placeboNCT00638716
1 other result
- -1.2 vs -0.4 NCT00674466
- HDG1901
- —Not posted · NCT06739044
HbA1c below 7%
- Albenatide
- —Not posted · NCT07058545
- HDG1901
- —Not posted · NCT06739044
Fasting plasma glucose, change
- Albenatide
- -0.8 vs -0.6−0.2 vs placeboNCT00638716
1 other result
- -0.3 vs 0.7 NCT00674466
- HDG1901
- —Not posted · NCT06739044
3-point MACE (% with event)
- Albenatide
- —Not posted · NCT07058545
- HDG1901
- —Not posted · NCT06739044
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Albenatide: 3 of 4 rows · HDG1901: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Albenatide | HDG1901 |
|---|---|---|
| Dropout rate | 14%1.5 mga NCT00638716 · Phase 2 · registry result, not featured evidence show 1 more result23.3%1.5 mg NCT00674466 · Phase 2 · registry result, not featured evidence | — |
| Discontinued due to AEs | —1.5 mga NCT00638716 · Phase 2 · registry result, not featured evidence show 1 more result—1.5 mg NCT00674466 · Phase 2 · registry result, not featured evidence | — |
| Serious AEs | 0%1.5 mga NCT00638716 · Phase 2 · registry result, not featured evidence show 1 more result3.3%1.5 mg NCT00674466 · Phase 2 · registry result, not featured evidence | — |
| Most frequent reported AEs | 1.5 mga nausea 22.4% (placebo 15.8%) diarrhea 12.2% (placebo 5.3%) vomiting 12.2% (placebo 3.5%) NCT00638716 · Phase 2 · registry result, not featured evidence show 1 more result1.5 mg headache 26.7% (placebo 24.1%) nausea 26.7% (placebo 13.8%) vomiting 23.3% (placebo 17.2%) NCT00674466 · Phase 2 · registry result, not featured evidence | — |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Albenatide
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Albenatide's landscape · HDG1901's landscape